China's NMPA has granted Porton Advanced Solutions a Class C Drug Manufacturing License, authorizing the Suzhou CDMO to begin commercial contract manufacturing of cell and gene therapy products. The license extends a platform of two GMP sites, more than 20,000 square meters of space, 10 viral…
China's National Medical Products Administration has granted Porton Advanced Solutions a Class C Drug Manufacturing License , authorizing the Suzhou-based contract development and manufacturing organization CDMO to produce cell and gene therapy CGT products for the commercial market. Porton Advanced announced the grant on 5 August 2026. The license covers commercial contract manufacturing for CGT products in China, an activity the company could not previously undertake: its services ran from process development through clinical production and stopped short of manufacturing therapies for sale.
Andrew Chen, Chief Executive Officer, Porton Advanced Solutions, said: "Obtaining the Class C Drug Manufacturing License is a pivotal milestone for Porton Advanced." Chen's framing treats the grant as validation of the company's quality systems, the working assumption being that a facility cleared for commercial manufacture has met an inspection bar that clinical-only production does not carry.
The transition from clinical to commercial manufacturing is the substantive step. Clinical-scale production runs in batches sized for trials, with processes still being locked down and release criteria that apply to a limited number of doses. Commercial manufacture requires reproducible output across many batches, audited supply chains, and quality systems that hold up under repeated regulatory inspection. The Class C grant is the regulator's statement that the facility, its suites, and its procedures are acceptable for that workload.
The company will bring the license to an already-built platform. Porton Advanced operates two good manufacturing practice GMP sites in Suzhou, China, holding more than 20,000 square meters of research, development, and manufacturing space. Inside that footprint sit 10 viral vector production lines and 12 GMP cell therapy suites, and the company counts more than 200 clients served globally.
GMP is the regulatory standard governing how facilities, equipment, personnel, and documentation are managed so that products are consistently produced to quality standards. The two Suzhou sites are GMP sites by the company's description; the Class C license is the regulator's confirmation that the company can operate to that standard for commercial supply. The license and the facility footprint are separate facts, and both appear in the announcement.
Scale matters because CGT manufacturing does not scale the way small-molecule synthesis does. Viral vectors are produced in cultured cells, harvested, purified through multiple chromatography steps, and filled under strict aseptic conditions. Each product typically needs dedicated or carefully segregated production trains, because cross-contamination between vectors is difficult to detect in a finished vial and could compromise both products. Installed square meters, line counts, and suite counts therefore determine how many client programs a CDMO can serve at once.
Two GMP sites add a layer of operational resilience that a single site cannot offer. If one site is shut down for contamination investigation or renovation, the other can keep producing, a consideration that matters when the products in question are the only therapy for some patients. The two-site structure also lets the company keep different clients' programs physically separate, a common requirement in contract manufacturing where competing sponsors use the same vendor. Neither benefit is stated in the announcement; both follow from the fact that there are two licensed sites.
Porton Advanced's platform spans plasmids, viral vectors, nucleic acid therapeutics, and exosome products, all within the broader category of advanced therapy medicinal products ATMPs that regulators group with cell and gene therapies. Plasmids are the upstream raw material for many viral vector and nucleic acid processes, so the company's plasmid capability feeds its own downstream lines. The 10 vector lines and 12 cell therapy suites tell a client something concrete: a CDMO at this scale can schedule several client programs in parallel, whereas a smaller operator would force programs into a queue.
The more than 200 clients served globally is a track record figure, not a current capacity figure. It does not reveal how many of those clients have programs in late-stage development with commercial launches approaching, nor which of them might be first to use the new license. The number does support the company's quality claim: a client base spanning multiple regulatory jurisdictions would have demanded documentation built to travel, consistent with the company's statement that its quality management system is designed to meet NMPA, U.S. Food and Drug Administration, and European Medicines Agency standards.
The practical change is narrow in wording and wide in effect. Before the grant, Porton Advanced was a development and clinical-stage manufacturer only: it could design a process, produce clinical trial material, and generate the data that supports an Investigational New Drug IND application, but it could not accept commercial contract manufacturing work. The Class C license extends its services through the commercialization stage, so a client can bring a program in at development and stay with the same manufacturer through launch supply.
The company says the license will let it deepen its focus on CGT CDMO services and offer a one-stop shop covering four stages:
Keeping all four stages under one roof removes the most common interruption in CGT development: the technology transfer between vendors that occurs when a program outgrows its development partner. Transfer risk is not abstract. Moving a cell or vector process between facilities can change product characteristics, and regulators require comparability evidence before accepting a new manufacturing site. A CDMO holding the license for the final stage can offer clients a single set of process documentation from the first transfection to the last commercial fill, and a single quality agreement that never has to be renegotiated mid-program.
Chen framed commercial supply as a scheduling exercise with clients, not a standalone corporate milestone. "We will align with our clients’ product launch schedules to prepare for commercial supply." The wording defines who controls the calendar. Under contract manufacturing, volumes and launch timing are set by the client's marketing authorization, not by the CDMO. Porton Advanced's commercial readiness is real, but the date commercial product leaves its Suzhou sites will be written by its clients' approval timelines and launch plans.
Porton Advanced is a services business. Its revenue follows client programs, and the Class C license lets it sell a service, commercial GMP manufacturing, that it could not sell before. The shift changes the shape of its contracts: development work is reimbursed in development timeframes, while commercial supply agreements run longer, at larger volumes, and under quality agreements that bind both parties for the product's market life. The license therefore does more than add a regulatory permission. It changes the duration and value of the company's relationships with clients.
The license is an administrative act with a specific regulatory meaning. The NMPA is China's national drug regulator, and the Drug Manufacturing License it issues authorizes an activity, the manufacture of drugs, at named facilities and under stated conditions. It is not a product approval. Every CGT product Porton Advanced will make still requires its own clinical trial authorization and its own marketing authorization from the NMPA before a patient can receive it. The Class C license determines who may be named as the manufacturer in those applications, not which medicines are approved.
The "C" in Class C reflects the structure of China's drug law. Since the 2019 revision of the Drug Administration Law, China has operated a marketing authorization holder MAH system in which the owner of a product and the maker of a product can be different companies. A marketing authorization holder commissions production; a separately licensed manufacturer performs it. The license category for a manufacturer that produces drugs on behalf of marketing authorization holders is Class C. Porton Advanced, as a contract development and manufacturing organization, does not own the CGT products it will make. Its clients do.
The MAH structure is recent for China. It was piloted before 2019, then written into the revised Drug Administration Law, and it changed the economics of drug development by letting sponsors hold product approvals without owning factories. For a CDMO, the system created a defined place in the regulatory architecture: one company can be the licensed manufacturer for many marketing authorization holders at once. That is the commercial position Porton Advanced is now taking.
For a sponsor that does not want to own a factory in China, the MAH system lowers the cost of market entry: the sponsor holds the product approval, and a licensed contract manufacturer produces the medicine. That arrangement makes the choice of manufacturer commercially decisive, because the product approval is tied to the approved manufacturing site, and changing sites later triggers comparability studies and renewed regulatory review. A client that moves a program into Porton Advanced under the new license is making a long-term commitment, not a short-term sourcing decision.
The grant binds Porton Advanced, not its clients' products. It commits the company to Chinese GMP requirements, to NMPA inspection, and to the conditions attached to the license itself. Each client's product still needs its own approval. What the grant changes is the ceiling: Porton Advanced can now be named the commercial manufacturer in a client's marketing authorization application in China, and can supply the market once that application succeeds.
Between the license and the first commercial batch lies a sequence of events outside the CDMO's control. The client's product must complete clinical development; the client must file a marketing authorization application naming Porton Advanced as the manufacturer; and regulators must approve both the product and the manufacturing arrangement. Process performance qualification runs, stability studies, and batch release testing all precede launch. The license is a necessary condition for commercial work, not a sufficient one.
The company says its quality management system is designed to meet NMPA, U.S. Food and Drug Administration, and European Medicines Agency standards. Chen's first statement ties the license to that system: the grant, in his telling, validates the quality systems the company has built. The argument is grounded in how inspections work. A Class C license follows an NMPA inspection of the facility, which examines the same kinds of documentation, training records, and validation protocols that FDA and EMA inspectors examine.
The claim is not a statement of authorization from the FDA or EMA. Meeting a foreign regulator's quality benchmark and holding that regulator's manufacturing authorization are different legal facts, and the announcement claims only the former. An FDA or EMA decision on a Chinese CDMO site would require a separate inspection and a separate finding, typically triggered by a client's marketing application in those jurisdictions.
For clients running globally aligned programs, the practical question is documentation. A quality system designed to three regulators' standards…
Related reading: Donald Bachem Obituary Notice: Wilmington, North Carolina, Manufacturing bottlenecks stall personalized neoantigen peptide vaccines, Neoantigen peptide vaccines face a purity-testing standards gap, Piramal Pharma Solutions expands peptide API facility with advanced spray drying suite.